# US 2015/0030538 A1 · Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0030538 A1
- Document ID: US20150030538A1
- Status: Published application
- Kind: A1
- Application number: 14/501,473
- Filed: 2014-09-30
- Published: 2015-01-29
- Earliest claimed: 2004-03-02
- Assignees: Cellectar, Inc.
- Applicants: Cellectar, Inc.
- Inventors: Jamey P. Weichert; Marc Longino; Anatoly Pinchuk
- Web page: https://patentgrep.com/patent/US20150030538A1

## CPC

- A61K 51/0408: {Phospholipids (liposomes encapsulating the radioactive probe or having no radiolabelled phospholipids A61K51/1231)}
- A61K 49/0017: {Fluorescence in vivo}
- A61K 51/04: Organic compounds
- C07F 13/005: {Compounds without a metal-carbon linkage}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method, comprising:
determining cancer in a subject to which 124I-labeled 18-(p-iodophenyl)octadecyl phosphocholine has been administered by determining 124I radioactivity in the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein the subject is human.

### Claim 23 (depends on 21)

The method of claim 21, comprising determining 124I-radioactivity using PET scanning.

### Claim 24 (depends on 21)

The method of claim 21, comprising determining 124I-radioactivity using SPECT scanning.

### Claim 25 (depends on 21)

The method of claim 21, comprising determining 124I-radioactivity using gamma camera scintigraphy.

### Claim 26 (depends on 21)

The method of claim 21, comprising determining 124I-radioactivity using MRI.

### Claim 27 (depends on 21)

The method of claim 21, comprising administering between about 0.5 μCi and about 500 mCi of the 124I-labeled 18-(p-iodophenyl)octadecyl phosphocholine to the subject.

### Claim 28 (depends on 21)

The method of claim 21, comprising administering less than 0.3 μg/kg of body weight of the 124I-labeled 18-(p-iodophenyl)octadecyl phosphocholine to the subject.

### Claim 29 (depends on 21)

The method of claim 21, wherein the cancer is lung cancer.

### Claim 30 (depends on 21)

The method of claim 21, wherein the cancer is adrenal cancer.

### Claim 31 (depends on 21)

The method of claim 21, wherein the cancer is melanoma or subcutaneous cancer.

### Claim 32 (depends on 21)

The method of claim 21, wherein the cancer is intestinal cancer, colon cancer or colorectal cancer.

### Claim 33 (depends on 21)

The method of claim 21, wherein the cancer is ovarian cancer or cervical cancer.

### Claim 34 (depends on 21)

The method of claim 21, wherein the cancer is prostate cancer.

### Claim 35 (depends on 21)

The method of claim 21, wherein the cancer is liver cancer or hepatocellular carcinoma.

### Claim 36 (depends on 21)

The method of claim 21, wherein the cancer is squamous cell carcinoma.

### Claim 37 (depends on 21)

The method of claim 21, wherein the cancer is retinoblastoma.

### Claim 38 (depends on 21)

The method of claim 21, wherein the cancer is glioma.

### Claim 39 (depends on 21)

The method of claim 21, wherein the cancer is breast cancer.

### Claim 40 (depends on 21)

The method of claim 21, wherein the cancer is carcinosarcoma.

### Claim 41 (depends on 21)

The method of claim 21, wherein the cancer is pancreatic cancer.

### Claim 42

A method of differentiating inflammation, adenoma, hyperplasia, or neoplasia in a subject, the method comprising:
providing a subject to which 124I-labeled 18-(p-iodophenyl)octadecyl phosphocholine has been administered; and
determining whether the subject has inflammation, adenoma, hyperplasia, or neoplasia by determining 124I radioactivity in the subject.

### Claim 43 (depends on 42)

The method of claim 42, comprising determining 124I-radioactivity using PET scanning.

### Claim 44 (depends on 42)

The method of claim 42, comprising determining 124I-radioactivity using SPECT scanning.

### Claim 45 (depends on 42)

The method of claim 42, comprising determining 124I-radioactivity using gamma camera scintigraphy.

### Claim 46 (depends on 42)

The method of claim 42, comprising determining 124I-radioactivity using MRI.

### Claim 47

A method for determining radiation- and chemo-insensitive cancer or cancer metastasis, comprising:
providing a subject to which 124I-labeled 18-(p-iodophenyl)octadecyl phosphocholine has been administered; and
determining whether the subject has radiation- and chemo-insensitive cancer or cancer metastasis by determining 124I radioactivity in the subject.

### Claim 48 (depends on 48)

The method of claim 48, comprising determining 124I-radioactivity using PET scanning.

### Claim 49 (depends on 48)

The method of claim 48, comprising determining 124I-radioactivity using SPECT scanning.

### Claim 50 (depends on 48)

The method of claim 48, comprising determining 124I-radioactivity using gamma camera scintigraphy.

### Claim 51 (depends on 48)

The method of claim 48, comprising determining 124I-radioactivity using MRI.
